Skip to main content

Table 4 Rates of Gram-negative resistant phenotypes collected from Latin America by country, 2004–2015

From: Antimicrobial susceptibility among Gram-positive and Gram-negative organisms collected from the Latin American region between 2004 and 2015 as part of the Tigecycline Evaluation and Surveillance Trial

Country

ESBL-producing K. pneumoniae

ESBL-producing K. oxytoca

ESBL-producing E. coli

βLPos H. influenzae

MDR A. baumannii

MDR P. aeruginosa

n/N

%

n/N

%

n/N

%

n/N

%

n/N

%

n/N

%

Central America

 Guatemala

153/253

60.5

3/8

37.5

163/414

39.4

2/16

12.5

150/189

79.4

103/235

43.8

 Honduras

56/76

73.7

1/1

100

31/78

39.7

2/8

25.0

39/51

76.5

15/47

31.9

 Panama

79/210

37.6

2/4

50.0

49/225

21.8

12/78

15.4

95/122

77.9

21/176

11.9

Rest of Latin America

 Argentina

367/869

42.2

14/83

16.9

133/949

14.0

109/468

23.3

465/573

81.2

192/749

25.6

 Brazil

122/270

45.2

3/26

11.5

51/300

17.0

19/96

19.8

148/174

85.1

73/232

31.5

 Chile

216/341

63.3

6/34

17.6

130/386

33.7

31/130

23.8

145/217

66.8

81/286

28.3

 Colombia

138/593

23.3

9/80

11.3

92/708

13.0

9/168

5.4

180/319

56.4

82/535

15.3

 Mexico

241/1025

23.5

23/152

15.1

510/1405

36.3

65/232

28.0

297/518

57.3

283/1035

27.3

 Venezuela

50/273

18.3

4/17

23.5

54/296

18.2

18/89

20.2

101/137

73.7

77/236

32.6

All Latin Americaa

1465/4032

36.3

67/409

16.4

1246/4912

25.4

270/1300

20.8

1654/2354

70.3

966/3613

26.7

  1. ESBL extended-spectrum β-lactamase, βLPos β-lactamase positive, MDR multidrug-resistant
  2. aIncludes all countries in Latin America that participated in T.E.S.T. Individual data for El Salvador, Nicaragua, Jamaica and Puerto Rico not present as contributed isolates in ≤2 years